Previous 10 | Next 10 |
Summary The market has swiftly priced in United Therapeutics Corporation's patent dispute. The company exhibits strong profitability momentum, with growth coming in at a low cost to earnings. It, therefore, feeds a high percentages of residual free cash flows to shareholders. Ne...
The following slide deck was published by United Therapeutics Corporation in conjunction with this event. For further details see: United Therapeutics (UTHR) Presents At 41st Annual Healthcare Conference - Slideshow
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. ...
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41 st annual J.P. Morgan Healthcare Conferen...
Summary Today, we take our first look at a biopharma concern called Liquidia Corporation. The company has a potential 'best of breed' product whose launch has been held up due to litigation challenges. Is the stock a buy for patient investors? An investment analysis follows in ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...
Summary Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept. On a 6-minut...
United Therapeutics (Nasdaq: UTHR ), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2023. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and indu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips You’ll often hear people say that bear markets are great for finding bargains, and that’s true. With the exception of energy, every major sector is in the red for the year. For its part, the iShares Biotechnolo...
United Therapeutics Corporation (UTHR) Q3 2022 Earnings Conference Call November 02, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer Michael Benkowitz – P...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...